These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30591489)

  • 21. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
    Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
    Han KH; Kim HS; Lee M; Chung HH; Song YS
    Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
    Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
    Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Nief CA; Hammer PM; Wang A; Charu V; Tanweer A; Litkouhi B; Kidd E; Gentles AJ; Howitt BE
    Clin Cancer Res; 2024 Jul; 30(13):2801-2811. PubMed ID: 38669067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
    Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.
    Asano H; Hatanaka KC; Matsuoka R; Dong P; Mitamura T; Konno Y; Kato T; Kobayashi N; Ihira K; Nozaki A; Oku A; Matsuno Y; Hatanaka Y; Watari H
    Ann Surg Oncol; 2020 Jul; 27(7):2159-2168. PubMed ID: 31792716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer.
    Han KH; Park NH; Kim HS; Chung HH; Kim JW; Song YS
    Gynecol Oncol; 2014 Aug; 134(2):293-6. PubMed ID: 24854062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis.
    Giannini A; D'Oria O; Corrado G; Bruno V; Sperduti I; Bogani G; Laganà AS; Chiantera V; Caserta D; Vizza E
    Arch Gynecol Obstet; 2024 Mar; 309(3):789-799. PubMed ID: 37454351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Romani C; Capoferri D; Reijnen C; Lonardi S; Ravaggi A; Ratti M; Bugatti M; Zanotti L; Tognon G; Sartori E; Odicino F; Calza S; Pijnenborg JMA; Bignotti E
    Int J Cancer; 2022 Aug; 151(4):637-648. PubMed ID: 35429348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer.
    Ichikawa T; Okugawa Y; Toiyama Y; Tanaka K; Yin C; Kitajima T; Kondo S; Shimura T; Ohi M; Araki T; Kusunoki M
    Br J Cancer; 2019 Dec; 121(12):1058-1068. PubMed ID: 31754264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L1CAM Is Not a Predictive Factor in Early-stage Squamous-cell Cervical Cancer.
    Romanová M; Židlík V; Javůrková V; Kondé A; Šimetka O; Klát J
    In Vivo; 2023; 37(5):2334-2339. PubMed ID: 37652517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Lymphovascular Space Invasion and Cytology in the Prognosis of Endometrial Cancer.
    Ozdemir CY; Arioz DT; Celik F; Cicekli N; Chkhikvadze M; Bilir F; Yılmaz S; Vatansever N
    Discov Med; 2024 Feb; 36(181):366-371. PubMed ID: 38409841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
    Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
    Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker.
    Vizza E; Mancini E; Laquintana V; Loria R; Carosi M; Baiocco E; Cicchillitti L; Piaggio G; Patrizi L; Sperduti I; Zampa A; Cutillo G; Falcioni R; Corrado G
    Surg Oncol; 2019 Mar; 28():151-157. PubMed ID: 30851892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas.
    Mancusi de Carvalho JP; Salim RC; Carvalho FM; Nogueira Dias Genta ML; Baracat EC; Carvalho JP
    J Clin Pathol; 2020 Nov; 73(11):748-753. PubMed ID: 32366597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
    Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
    Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L1CAM expression in colorectal cancer identifies a high-risk group of patients with dismal prognosis already in early-stage disease.
    Tampakis A; Tampaki EC; Nonni A; Tsourouflis G; Posabella A; Patsouris E; Kontzoglou K; von Flüe M; Nikiteas N; Kouraklis G
    Acta Oncol; 2020 Jan; 59(1):55-59. PubMed ID: 31532272
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Aro K; Pasanen A; Bützow R; Loukovaara M
    Gynecol Oncol; 2024 Oct; 189():9-15. PubMed ID: 38972089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.